logo image
search icon
Targeted Protein Degradation Market

Targeted Protein Degradation Market Share & Trends Analysis Report, Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), By Region, and Segment Forecasts, 2023-2031

Report ID : 2530 | Published : 2024-06-12 | Pages: 180 | Format: PDF/EXCEL

Targeted Protein Degradation Market Size is valued at USD 0.42 Bn in 2023 and is predicted to reach USD 2.65 Bn by the year 2031 at an 26.3% CAGR during the forecast period for 2024-2031.

Targeted Protein Degradation Market info

Targeted Protein Degradation (TPD) is a novel therapeutic strategy that harnesses the cell's natural protein disposal system to eliminate unwanted proteins. Instead of inhibiting a protein's activity, TPD molecules tag the protein for destruction by the proteasome, a cellular machine responsible for breaking down proteins. Targeted protein degradation (TPD) is a cutting-edge drug discovery strategy that eliminates problematic proteins from cells by leveraging cellular degradation processes using small molecules. One such process is the ubiquitin-proteasome pathway, a quality control mechanism that tags damaged or misfolded proteins for destruction by the proteasome.

The field of TPD is witnessing continuous advancements in areas like degrader design, leading to more potent and selective molecules with the ability to target a wider range of proteins. Additionally, research is ongoing to overcome challenges like off-target effects and delivery methods, further strengthening the market's potential. Encouraging results from ongoing clinical trials involving TPD therapies boost investor confidence and accelerate market growth. As more drugs successfully navigate clinical trials and reach patients, the market is poised for significant expansion.

Competitive Landscape

Some of the Major Key Players in the Targeted Protein Degradation Market are

  • Arvinas
  • Bristol-Myers Squibb
  • C4 Therapeutics
  • Loxo Oncology
  • Olema Oncology
  • Radius Health
  • AstraZeneca
  • Roche
  • BeiGene
  • InnoCare Pharma
  • Kangpu Biopharmaceuticals
  • Kintor Pharmaceuticals
  • Medivir
  • Monte Rosa Therapeutics
  • Ranok Therapeutics
  • Sanofi
  • Zentalis Pharmaceuticals
  • Eisai Therapeutics

Market Segmentation:

The PROTAC segment is Expected to have the highest growth rate during the forecast period

Based on the distribution by type of degrader categorized into SERD, PROTAC and molecular glue. Among these, the PROTAC segment is expected to have the highest growth rate during the forecast period. PROTACs cleverly leverage the cell's existing protein disposal system, the ubiquitin-proteasome pathway. This inherent cellular mechanism provides a powerful and efficient method to degrade target proteins, making PROTACs a highly attractive therapeutic approach. Ongoing research and clinical trials involving PROTACs are yielding encouraging results, which in turn fuels investor confidence and accelerates the development of PROTAC-based therapies. This growing scenario is propelling the market forward, highlighting the potential of PROTACs to transform the landscape of disease treatment.

The Breast Cancer Segment Dominate the Market

Target indications are categorized as breast cancer and multiple myeloma. The breast cancer segment dominates the market. Breast cancer research has provided fertile ground for the targeted protein degradation (TPD) market.  The identification of key protein targets involved in breast cancer growth, like hormone receptors and cell proliferation proteins, makes them prime candidates for TPD strategies using PROTACs. Early success in clinical trials with these PROTACs has fueled significant investor interest and further research, solidifying breast cancer as the leading player in the TPD market. TPD therapies using PROTACs have the potential to work synergistically with existing breast cancer treatments like chemotherapy and targeted therapies. This opens doors for developing combination regimens with potentially improved efficacy and outcomes.

North America Led the Targeted Protein Degradation Market

North America faces significant limitations of chronic diseases like cancer and neurodegenerative diseases, which are potential targets for TPD therapies. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth. North American countries are generally more receptive to adopting new and innovative healthcare technologies. This openness allows for faster clinical trial approvals and earlier access to promising TPD therapies for patients.

Recent Developments:

  • In April 2024, Arvinas, Inc., announced that it has signed an exclusive strategic license agreement with Novartis for the global development and commercialization of ARV-766, Arvinas' second-generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. is a clinical-stage biotechnology company developing a new class of drugs based on targeted protein degradation. An asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis is also a part of the transaction.
  • In September, 2023, Bristol Myers Squibb is hosting a Research and Development (R&D) Day in New York to discuss the company's R&D capabilities and strategy to provide information about its strong pipeline that supports sustainable long-term growth. The company's leadership team will also showcase its improved R&D framework and unique research platforms, which are anticipated to provide exceptional productivity that produces top-notch early-stage candidates and noticeably shortens R&D timelines.

Targeted Protein Degradation Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 0.42 Bn

Revenue Forecast In 2031

USD 2.65 Bn

Growth Rate CAGR

CAGR of 26.3% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Distribution by Type of Degrader, Target Indication

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia

Competitive Landscape

Arvinas, Bristol-Myers Squibb, C4 Therapeutics,Loxo Oncology, Olema Oncology, Radius Health,AstraZeneca, Roche, BeiGene, InnoCare Pharma,Kangpu Biopharmaceuticals, Kintor Pharmaceuticals, Medivir, Monte Rosa Therapeutics, Ranok Therapeutics, Sanofi, Zentalis Pharmaceuticals, Eisai Therapeutics

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Targeted Protein Degradation Market Snapshot

Chapter 4. Global Targeted Protein Degradation Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Type of Degrader Estimates & Trend Analysis

5.1. by Type of Degrader & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type of Degrader:

5.2.1. SERD

5.2.2. PROTAC

5.2.3. Molecular Glue

Chapter 6. Market Segmentation 2: by Target Indication Estimates & Trend Analysis

6.1. by Target Indication & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Target Indication:

6.2.1. Breast Cancer

6.2.2. Myeloma

Chapter 7. Targeted Protein Degradation Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Type of Degrader, 2024-2031

7.1.2. North America Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2024-2031

7.1.3. North America Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

7.2. Europe

7.2.1. Europe Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Type of Degrader, 2024-2031

7.2.2. Europe Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2024-2031

7.2.3. Europe Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

7.3. Asia Pacific

7.3.1. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Type of Degrader, 2024-2031

7.3.2. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2024-2031

7.3.3. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

7.4. Latin America

7.4.1. Latin America Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Type of Degrader, 2024-2031

7.4.2. Latin America Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2024-2031

7.4.3. Latin America Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Type of Degrader, 2024-2031

7.5.2. Middle East & Africa Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2024-2031

7.5.3. Middle East & Africa Targeted Protein Degradation Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Arvinas

8.2.2. Bristol-Myers Squibb

8.2.3. C4 Therapeutics

8.2.4. Loxo Oncology

8.2.5. Olema Oncology

8.2.6. Radius Health

8.2.7. AstraZeneca

8.2.8. Roche

8.2.9. BeiGene

8.2.10. InnoCare Pharma

8.2.11. Kangpu Biopharmaceuticals

8.2.12. Kintor Pharmaceuticals

8.2.13. Medivir

8.2.14. Monte Rosa Therapeutics

8.2.15. Ranok Therapeutics

8.2.16. Sanofi

8.2.17. Zentalis Pharmaceuticals

8.2.18. Eisai Therapeutics

8.2.19. Other Prominent Players

Segmentation of Targeted Protein Degradation Market

Global Targeted Protein Degradation Market –By Type of Degrader

  • SERD
  • PROTAC
  • Molecular Glue

Targeted Protein Degradation Market seg

Global Targeted Protein Degradation Market – Target Indication

  • Breast Cancer
  • Multiple Myeloma

Global Targeted Protein Degradation Market – By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Targeted Protein Degradation Market Size?

Targeted Protein Degradation Market is predicted to develop at an 26.3% CAGR during the forecast period for 2024-2031.

Kangpu Biopharmaceuticals, Kintor Pharmaceuticals, Medivir, Monte Rosa Therapeutics, Ranok Therapeutics, Sanofi, Zentalis Pharmaceuticals, Eisai Thera

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach